Oral administration of 0.05% SA reduced body weight, visceral fat mass, serum levels of leptin, tumor necrosis factor-α, interferon-γ, interleukin-6, monocyte chemoattractant protein 1 (MCP-1), insulin resistance (IR), hepatic lipid content, droplets, and early fibrosis [19]. This evidence concerns the gene CCL2 and Insulin resistance.